Home
Online Library
Uptodate
Journal
Educational Video
Buy A Package
Uptodate
Journal
Main Language Online Library
Persian Online Library
Educational Video
Office And Clinic Software
Turn Ratings
About Us
Contact Us
Login
Register
Return To The Previous Page
Buy a Package
Number Of Visible Items Remaining : 3 Item
Version October 2024
Search
Uptodate Reference Title
Go To Link
Close
TP53 mutations and treatment outcome in CLL
TP53 mutations and treatment outcome in CLL
Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) according to TP53 mutation status in patients with chronic lymphocytic leukemia (CLL) initially treated with fludarabine, cyclophosphamide, and rituximab.
FCR: fludarabine, cyclophosphamide, and rituximab; PFS: progression-free survival; OS: overall survival;
TP53
WT
: wild-type
TP53
;
TP53
mut
: mutant
TP53.
This research was originally published in Blood. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123:3247. Copyright © 2014 American Society of Hematology.
Graphic 108430 Version 1.0
×
کتابخانه آنلاین و چاپی زبان اصلی
کتاب چاپی فارسی
ژورنال
ویديو آموزش
آپتودیت
کتابخانه آنلاین فارسی
Search
Do you want to add Medilib to your home screen?
Yes Please
No Thanks
Add Medilib to home screen